The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status

被引:22
|
作者
Shafrir, Amy L. [1 ,2 ,3 ]
Rice, Megan S. [2 ,3 ,4 ]
Gupta, Mamta [5 ,6 ]
Terry, Kathryn L. [1 ,7 ,8 ]
Rosner, Bernard A. [2 ,3 ,9 ]
Tamimi, Rulla M. [1 ,2 ,3 ]
Hecht, Jonathan L. [5 ,6 ]
Tworoger, Shelley S. [1 ,2 ,3 ]
机构
[1] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 181 Longwood Ave, Boston, MA USA
[3] Harvard Med Sch, 181 Longwood Ave, Boston, MA USA
[4] Massachusetts Gen Hosp, Dept Med, Clin & Translat Epidemiol Unit, 55 Fruit St, Boston, MA USA
[5] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA
[6] Harvard Med Sch, 330 Brookline Ave, Boston, MA USA
[7] Brigham & Womens Hosp, Dept Obstet & Gynecol, Obstet & Gynecol Epidemiol Ctr, 221 Longwood Ave, Boston, MA USA
[8] Harvard Med Sch, 221 Longwood Ave, Boston, MA USA
[9] Harvard TH Chan Sch Publ Hlth, Dept Biostat, 677 Huntington Ave, Boston, MA USA
基金
美国国家卫生研究院;
关键词
BREAST-CANCER; RISK-FACTORS; EXPRESSION; CELL; CARCINOMA; SUBTYPES;
D O I
10.1016/j.ygyno.2016.09.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. We assessed the association between reproductive and hormonal factors and ovarian cancer incidence characterized by estrogen receptor-alpha (ER alpha) and progesterone receptor (PR) status. Methods. Tissue microarrays were used to assess ERa and PR expression among 197 Nurses' Health Study (NHS), 42 NHSII and 76 New England Case-Control Study (NECC) ovarian cancer cases. NHS/NHSII cases were matched to up to 4 controls (n = 954) on diagnosis date and birth year. NECC controls (n = 725) were frequency matched on age. Cases were considered receptor positive if of tumor cells stained positive. Associations by ER alpha and PR status were assessed using polytomous logistic regression. p-Value for heterogeneity was calculated using a likelihood ratio test. Results. 45% of ovarian tumors were PR( +), 78% were ERa (+) and 45% were ER alpha(+)/PR(+), while 22% were ER alpha(-)/PR(-). Postmenopausal status was associated with an increased risk of PR(-) tumors (OR: 2.07; 95%CI: 1.15-3.75; p-heterogeneity = 0.01) and age at natural menopause was inversely associated with PR(-) tumors (OR, per 5 years: 0.77; 95%CI: 0.61-0.96; p-het = 0.01). Increasing duration of postmenopause was differentially associated by PR status (p-het = 0.0009). Number of children and tubal ligation were more strongly associated with ERa(-) versus ER alpha (+) tumors (p-het = 0.002 and 0.05, respectively). No differential associations were observed for oral contraceptive or hormone therapy use. Conclusions. Postmenopausal women have an increased risk of developing PR(-) ovarian tumors compared to premenopausal women. The associations observed for ovarian cancer differ from those seen for breast cancer suggesting that the biology for tumor development through ERa and PR pathways may differ. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:628 / 635
页数:8
相关论文
共 50 条
  • [21] Discordant Estrogen and Progesterone Receptor Status in Breast Cancer
    Hefti, M. M.
    Hu, R.
    Knoblauch, N.
    Collins, L.
    Tamimi, R. M.
    Beck, A. H.
    CANCER RESEARCH, 2012, 72
  • [22] Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: A meta-analysis of epidemiological studies
    Ma H.
    Bernstein L.
    Pike M.C.
    Ursin G.
    Breast Cancer Research, 8 (4)
  • [23] Estrogen receptor and progesterone receptor status: differences between primary and metastatic breast cancer.
    Glass, EL
    Heffelfinger, S
    Blau, R
    Lower, EE
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S60 - S60
  • [24] Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen
    Langdon, SP
    Gabra, H
    Bartlett, JMS
    Rabiaz, GJ
    Hawkins, RA
    Tesdale, AL
    Ritchie, AA
    Miller, WR
    Smyth, JF
    CLINICAL CANCER RESEARCH, 1998, 4 (09) : 2245 - 2251
  • [25] Estrogen- and estrogen receptor (ER)-mediated cisplatin chemoresistance in cancer
    Berkel, Caglar
    Cacan, Ercan
    LIFE SCIENCES, 2021, 286
  • [26] Estrogen-α and progesterone receptor expression in cystic endometrial hyperplasia and pyometra in the bitch
    De Bosschere, H
    Ducatelle, R
    Vermeirsch, H
    Simoens, P
    Coryn, M
    ANIMAL REPRODUCTION SCIENCE, 2002, 70 (3-4) : 251 - 259
  • [27] Estrogen Receptor-β Expression of Ovarian Tumors and Its Association with Ovarian Cancer Risk Factors
    Shafrir, Amy L.
    Babic, Ana
    Kuliszewski, Margaret Gates
    Rice, Megan S.
    Townsend, Mary K.
    Hecht, Jonathan L.
    Tworoger, Shelley S.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (11) : 2211 - 2219
  • [28] Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status
    Huang, WY
    Newman, B
    Millikan, RC
    Schell, MJ
    Hulka, BS
    Moorman, PG
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2000, 151 (07) : 703 - 714
  • [29] Hormone-related factors and risk of breast cancer by estrogen receptor and progesterone receptor status.
    Huang, WY
    Newman, B
    Millikan, RC
    Schell, MJ
    Moorman, PG
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1998, 147 (11) : S35 - S35
  • [30] Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer
    Oudanonh, Thiphavone
    Nabi, Hermann
    Ennour-Idrissi, Kaoutar
    Lemieux, Julie
    Diorio, Caroline
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (10) : 2736 - 2745